Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01315678|
Recruitment Status : Completed
First Posted : March 15, 2011
Results First Posted : June 24, 2019
Last Update Posted : June 24, 2019
A major factor in the respiratory health of Cystic Fibrosis (CF) subjects is the prevalence of chronic Pseudomonas aeruginosa (Pa) infections. The Pa infection rate in CF patients increases with age and by age 18 years approximately 85% of CF patients in the US are infected. Liposomal amikacin for inhalation (Arikayce™) was developed as a possible treatment for chronic infection due to Pa in CF patients.
The purpose of this study is to determine whether Arikayce™ is effective in treating chronic lung infections caused by Pa in CF subjects. The effectiveness, safety, and tolerability of Arikayce™ will be compared to Tobramycin TOBI®, an inhalation antibiotic already available for use.
|Condition or disease||Intervention/treatment||Phase|
|Pseudomonas Aeruginosa Infection||Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. Drug: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.||Phase 3|
CF is a genetic disease resulting from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with CF manifest pathological changes in a variety of organs that express CFTR. The lungs are frequently affected often resulting in chronic infections by bacteria such as Pseudomonas aeruginosa and airway inflammation. Treatment of chronic lung infections is one of the principal goals of CF therapy. Arikayce™ LAI (liposomal amikacin for inhalation) is a sustained-release formulation of amikacin encapsulated inside nanoscale liposomal carriers designed for administration via inhalation. It is hypothesized that the sustained-release pulmonary targeting and biofilm penetration properties of this formulation will have several advantages over current therapies in treating CF patients with chronic lung infection caused by Pseudomonas aeruginosa.
This Phase 3 study has been designed to evaluate the efficacy, safety and tolerability of Arikayce™ in treating CF patients with chronic bronchopulmonary infection compared to a currently available antibiotic, TOBI® Inhalation Solution. Eligible subjects will be randomized 1:1 to receive 590 mg of Arikayce™ once daily via a PARI Investigational eFlow® Nebulizer or 300 mg TOBI® BID via a PARI LC® PLUS nebulizer. Subjects will receive 3 cycles of treatment with each cycle being comprised of 28 days on treatment followed by 28 days off-treatment. Total study duration is up to 186 days (~6 months) including an up to 18 day Screening period. Subjects will be evaluated for safety, tolerability and efficacy bi-weekly during the first 4 weeks of treatment, and thereafter every 4 weeks for the duration of the study. Pharmacokinetics (PK) of Arikayce™ in blood, sputum and 24-hour urine will be determined in a subgroup of study subjects who consent to PK evaluation.
At the completion of the TR02-108 protocol, subjects who have consented and meet study safety criteria may enroll in the long-term, open-label, multi-cycle extension study of 590 mg of Arikayce™ (under a separate protocol TR02-110). Arikace™, Arikayce™, Liposomal Amikacin for Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used interchangeably throughout this study and other studies evaluating amikacin liposome inhalation suspension.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||302 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa|
|Actual Study Start Date :||February 29, 2012|
|Actual Primary Completion Date :||June 2013|
|Actual Study Completion Date :||September 18, 2013|
Arikayce™ is liposomal amikacin for inhalation
Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
Active Comparator: TOBI®
TOBI® is tobramycin inhalation solution
Drug: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
- Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Baseline to168 days ]Relative Change (%) from baseline to end of study (Day 168) in FEV1 (1 second)
- Pumonary Function Test: Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168. ]Relative changes (%) from baseline to Study Days 14, 28, 57, 84, 113, 140, 168 in FEV1
- Number of Subjects Experiencing a Pulmonary Exacerbation [ Time Frame: 168 days ]Number of Subjects experiencing a pulmonary exacerbation measured by number with event and number censored
- Number of Subjects to First Antipseudomonal Antibiotic Treatment for Pulmonary Exacerbation [ Time Frame: 168 days ]Number of Subjects to first antipseudomonal antibiotic treatment for pulmonary exacerbation measured by number with event and number censored
- Number of Subjects to First All Cause Hospitalization [ Time Frame: 168 days ]Number of Subjects to first all cause hospitalization measured by number with event and number censored
- Change in Density (Log CFU) in Pseudomonas Aeruginosa in Sputum [ Time Frame: Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168 ]Change in density (Log CFU) from baseline in Pseudomonas aeruginosa in sputum
- Relative Percent (%) Change in Respiratory Symptoms as Measured by the CFQ-R [ Time Frame: Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168 ]Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315678
|Study Director:||Gina Eagle, MD||Insmed Incorporated|